- Home
- GYRE vs WOOF Comparison
GYRE vs WOOF Comparison
Compare GYRE & WOOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GYRE | WOOF |
|---|---|---|
| Founded | 2002 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 759.1M | 871.9M |
| IPO Year | 2004 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GYRE | WOOF |
|---|---|---|
| Price | $7.55 | $3.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $17.00 | $3.90 |
| AVG Volume (30 Days) | 100.7K | ★ 2.8M |
| Earning Date | 06-18-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 103.55 | 92.26 |
| EPS | 0.04 | 0.04 |
| Revenue | $275,000.00 | ★ $6,116,462,000.00 |
| Revenue This Year | $11.59 | $2.61 |
| Revenue Next Year | $26.31 | $1.63 |
| P/E Ratio | $195.13 | ★ $81.51 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.11 | $2.24 |
| 52 Week High | $12.42 | $4.19 |
Technical Indicators
Market Signals| Indicator | GYRE | WOOF |
|---|---|---|
| Relative Strength Index (RSI) | 42.88 | 78.30 |
| Support Level | $7.07 | $3.32 |
| Resistance Level | $8.25 | $3.70 |
| Average True Range (ATR) | 0.61 | 0.18 |
| MACD | -0.08 | 0.11 |
| Stochastic Oscillator | 4.50 | 88.31 |
Price Performance
Historical ComparisonAbout GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About WOOF Petco Health and Wellness Company Inc.
Petco Health and Wellness Co Inc is a pet specialty retailer focused on improving the lives of pets, pet parents, and its own partners with pet care centers in approximately 50 states, the District of Columbia and Puerto Rico. The Company also offers an expanded range of consumables, supplies, and services through its website and mobile app.